Zimbabwe has declined a significant American health deal worth $367m (272 million pounds) over five years because of the United States' demand for confidential data.
The decision came to light following a official document dated December was disclosed, revealing that President Emmerson Mnangagwa deemed the arrangement was "skewed".
A government representative later stated that the United States was seeking health data for scientific study and profit while was unwilling to guarantee the resulting advantages from any future vaccines.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged more dialogue to reach a agreement acceptable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
This rejection follows a similar situation in Kenya, where a high court suspended a similar deal with the US after legal challenges were filed about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump claimed its spending was "inefficient" and his government was seeking direct bilateral deals to boost transparency and responsibility.
As per reports, Sixteen African countries have to date agreed to these new health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, without any corresponding assurance of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"Put simply, our nation would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our people should a new pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining structures previously established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is intended to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to continued discussions with our American counterparts on how future co-operation might be arranged in a manner that respects the independence and interests of both nations."
Medical Community Response
A leading public health body expressed it recognised the government's concerns, but recommended that talks need to persist given that a large portion of the nation's Aids initiatives relied on external financing.
"Where technical issues arise, such as those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The situation underscores the ongoing tensions between receiving much-needed international aid and protecting a country's data in an increasingly data-driven world.